Trial Profile

Utilizing Continuous Glucose Monitoring (CGM) to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary)
Indications Advanced breast cancer; Breast cancer; HER2 negative breast cancer
Focus Adverse reactions

Most Recent Events

03 Jun 2025 Planned End Date changed from 13 Jun 2025 to 1 Oct 2025.
09 Dec 2024 Planned End Date changed from 1 Jun 2025 to 13 Jun 2025.
09 Dec 2024 Planned primary completion date changed from 1 Jun 2025 to 13 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com